Table 3.
Clinical cases of PEM-induced irAEs
| Clinical Case, Year Reported | Age/Sex (M/F) | PEM Oncological Indication | Reported PEM-Induced CVD Clinical Indications | PEM-Induced irAEs Clinical Presentation |
|---|---|---|---|---|
| Case 1, 2021 (145) | 75 | Malignant mesothelioma |
|
|
| Case 2, 2021 (60) | 49/F | Thymoma |
|
|
| 70/M | Bladder cancer |
|
|
|
| 75/M | Chondroma of SACRUM |
|
|
|
| Case 3, 2021 (146) | 83/M | Advanced nonsmall cell lung cancer |
|
|
| Case 4, 2020 (147) | 79/M | Metastatic melanoma |
|
|
| 69/M | Metastatic urothelial carcinoma |
|
|
|
| 89/M | Nonsmall cell lung cancer |
|
|
|
| Case 5, 2020 (148) | 75/M | Lung adenocarcinoma |
|
|
| Case 6, 2020 (149) | 69/M | Urothelial carcinoma |
|
|
| Case 7, 2020 (150) | 77/M | Metastatic melanoma |
|
|
| Case 8, 2020 (151) | 63/M | Bladder tumor |
|
|
| Case 9, 2020 (152) | 70/F | Thymic carcinoma |
|
|
| Case 10, 2019 (153) | 83/M | Urothelial carcinoma |
|
|
| Case 11, 2019 (154) | 70/M | Squamous cell carcinoma of the right lung |
|
|
| Case 12, 2019 (155) | 58/F | Metastatic thymoma |
|
|
| 30/F | Metastatic B3 thymoma |
|
|
|
| Case 13, 2019 (156) | 83/M | Metastatic melanoma |
|
|
| Case 14, 2018 (157) | 67/F | Multiple myeloma |
|
|
| Case 15, 2018 (158) | 79/M | Metastatic gastric adenocarcinoma |
|
|
| Case 16, 2017 (159) | 78/M | Metastatic melanoma |
|
|
| Case 17, 2017 (160) | 82/M | Melanoma |
|
|
| Case 18, 2016 (161) | 86/F | Metastatic melanoma |
|
|
BNP, brain natriuretic peptide; CK, creatine kinase; CK‐MB, creatine kinase myocardial band; CVD, cardiovascular disease; EF, ejection fraction; EKG, echocardiogram; irAEs, immune‐related adverse events; LDH, lactose dehydrogenase; LVEF, left ventricular ejection fraction; NSTEMI, non‐ST‐elevation myocardial infarction; PEM, pembrolizumab.